Last reviewed · How we verify
NCT06105814: COPEXNOR
Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NA trial testing Rapid diagnostics in Chronic Obstructive Pulmonary Disease Exacerbation in 200 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Vestre Viken Hospital Trust |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | diagnostic |
| Enrollment | 200 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2030 |
Drugs / interventions tested
- Rapid diagnostics
Conditions studied
- Chronic Obstructive Pulmonary Disease Exacerbation — all drugs for Chronic Obstructive Pulmonary Disease Exacerbation →
- Pneumonia — all drugs for Pneumonia →
- Respiratory Tract Infections — all drugs for Respiratory Tract Infections →
Sponsor
Vestre Viken Hospital Trust
Who can join
18 and older, any sex, with Chronic Obstructive Pulmonary Disease Exacerbation or Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive pulmonary disease, where inflammation and recurrent infections are key pathophysiological contibutors in disease progression. Acute exacerbations of COPD (AECOPD) are often treated with antibiotics, even though only about 50% are caused by bacteria, and the evidence for benefit of empiric antibiotic treatment in AECOPD is conflicting. Microbiological sampling is often insufficient in the setting of AECOPD, and there is a lack of biomarkers distinguishing AECOPD caused by bacteria from those not caused by bacteria, leaving the clinician with few tools to guide the use of antibiotics. Overuse of antibiotics is the main driver of antimicrobial resistance (AMR), a major global public health threat, and obtaining the correct microbiological diagnose is important in guiding treatment of AECOPD. COPEXNOR seeks to examine which samples give the highest microbiological yield in AECOPD, comparing induced sputum to nasopharyngeal swabs. We will also compare conventional microbiological diagnostics to modern rapid molecular microbiological tests, to evaluate if faster microbiological diagnosis improves antibiotic stewardship. The study aims to define the microbiological etiology causing AECOPD in the Norwegian COPD-population, and examine the lung microbiome over time. COPEXNOR will explore biomarkers in sputum and blood that can be useful for differentiating patients who will benefit from antibiotic treatment from patients who will not.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06105814
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Vestre Viken Hospital Trust trials
Trials by the same sponsor.
- NCT07200713 — Effect Study of SMART Treatment for Youth · NA · not yet recruiting
- NCT06906419 — Arthroscopic Trochleaplasty in Chronic Relapsing Patellar Dislocations: A Follow-up Study · enrolling by invitation
- NCT06920654 — Stabilization of the Shoulder Joint Using a Latarjet-like Procedure. · enrolling by invitation
- NCT06738381 — Digital Secondary Prevention After Atherosclerotic Cardiovascular Disease · NA · recruiting
- NCT06912061 — A Needle Technique for Achilles Tendon Lengthening in Pediatric Patients: A Prospective Study on Efficacy, Safety, and F · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06105814 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vestre Viken Hospital Trust
- Last refreshed: 30 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06105814.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing